结核与肺部疾病杂志 ›› 2024, Vol. 5 ›› Issue (4): 289-293.doi: 10.19983/j.issn.2096-8493.2024039

• 论著 • 上一篇    下一篇

国产结核分枝杆菌T细胞免疫反应检测试剂盒诊断结核病的临床试验研究

梁亚萍1, 王卓1, 刘家云2, 朱蕾1, 李静1, 李蒙1, 仵倩红3()   

  1. 1陕西省结核病防治院检验科,西安 610100
    2第四军医大学第一附属医院检验科,西安 710032
    3陕西省第二人民医院老年医学科,西安 710005
  • 收稿日期:2024-02-01 出版日期:2024-08-20 发布日期:2024-08-13
  • 通信作者: 仵倩红 E-mail:15902969531@126.com
  • 基金资助:
    国家重点研发计划(2022YFC2603705)

Clinical trial study of a Chinese domestic tuberculous bacillus T-cell immune response detection kit

Liang Yaping1, Wang Zhuo1, Liu Jiayun2, Zhu Lei1, Li Jing1, Li Meng1, Wu Qianhong3()   

  1. 1Department of Clinical Laboratory, Tuberculosis Hospital of Shaanxi Province, Xi’an 610100, China
    2Department of Clinical Laboratory, the First Affiliated Hospital of the Fourth Military Medical University, Xi’an 710032, China
    3Department of Geriatrics, Shaanxi Provincial Second People’s Hospital, Xi’an 710005, China
  • Received:2024-02-01 Online:2024-08-20 Published:2024-08-13
  • Contact: Wu Qianhong E-mail:15902969531@126.com
  • Supported by:
    National Key Research and Development Program(2022YFC2603705)

摘要:

目的:评价国产结核分枝杆菌T细胞免疫反应检测试剂盒(简称“试验试剂盒”)在体外定性检测疑似结核病患者新鲜外周静脉抗凝血中结核分枝杆菌特异性T细胞免疫反应结果的检测效能。方法:采用国产试验试剂盒与已上市进口产品(简称“对照试剂盒”),针对2020年11月至2021年6月陕西省结核病防治院收治的335例及2021年7月至2022年6月第四军医大学第一附属医院收治的343例疑似结核病患者的新鲜外周静脉抗凝血进行检测效能的比较研究。结果:678例外周静脉抗凝血样本中,以对照试剂盒为参考标准,试验试剂盒检测的敏感度为93.97%(327/348),特异度为96.06%(317/330),一致率为94.99%(644/678);以病原学诊断和临床诊断结果为参考标准,试验试剂盒检测的敏感度为82.93%(277/334),特异度为81.69%(281/344),一致率为82.30%(558/678),对照试剂盒检测的敏感度为87.13%(291/334),特异度为83.43%(287/344),一致率为85.25%(578/678);204例病原学阳性患者外周静脉抗凝血样本中,试验试剂盒的结核病检出率为82.35%(168/204),对照试剂盒的结核病检出率为88.24%(180/204);130例病原学阴性患者的外周静脉抗凝血样本中,试验试剂盒的结核病检出率为83.85%(109/130),对照试剂盒的结核病检出率为85.38%(111/130);在344例非结核肺部疾病患者外周静脉抗凝血样本中,两种试剂盒检测的一致率为95.35%(328/344),试验试剂盒检测的特异度为81.69%(281/344),对照试剂盒检测的特异度为83.43%(287/344)。结论:国产结核分枝杆菌T细胞免疫反应检测试剂盒与进口已上市试剂盒,对疑似结核病患者新鲜外周静脉抗凝血体外检测结核分枝杆菌特异性T细胞免疫反应的结果具有较高的一致性,可以作为疑似结核病患者的替代诊断工具。

关键词: 结核, 酶联免疫斑点测定, 试剂盒, 诊断, 敏感性与特异性

Abstract:

Objective: To evaluate the performance of a domestically produced Mycobacterium tuberculosis (MTB) T-cell immune response test kit (referred to as the “test kit”) for in vitro qualitative detection of MTB-specific T-cell immune responses in fresh peripheral venous anticoagulated blood from suspected tuberculosis patients. Methods: A comparative study was conducted using the domestic test kit and an already marketed imported product (referred to as the “control kit”). The study included 335 suspected tuberculosis patients treated at the Shaanxi Provincial Tuberculosis Hospital from November 2020 to June 2021, and 343 suspected tuberculosis patients treated at the First Affiliated Hospital of the Fourth Military Medical University from July 2021 to June 2022. Results: Among the 678 peripheral venous anticoagulated blood samples, using the control kit as the reference standard, the test kit showed a sensitivity of 93.97% (327/348), a specificity of 96.06% (317/330), and an overall agreement rate of 94.99% (644/678). When using pathogen diagnosis and clinical diagnosis as reference standards, the test kit showed a sensitivity of 82.93% (277/334), a specificity of 81.69% (281/344), and an overall agreement rate of 82.30% (558/678). In comparison, the control kit showed a sensitivity of 87.13% (291/334), a specificity of 83.43% (287/344), and an overall agreement rate of 85.25% (578/678). Among the 204 peripheral venous anticoagulated blood samples from pathogen-positive patients, the tuberculosis detection rate was 82.35% (168/204) for the test kit and 88.24% (180/204) for the control kit. Among the 130 peripheral venous anticoagulated blood samples from pathogen-negative patients, the tuberculosis detection rate was 83.85% (109/130) for the test kit and 85.38% (111/130) for the control kit. For the 344 peripheral venous anticoagulated blood samples from patients with non-tuberculous pulmonary diseases, the agreement rate between the two kits was 95.35% (328/344). The specificity was 81.69% (281/344) for the test kit and 83.43% (287/344) for the control kit. Conclusion: The domestic MTB T-cell immune response test kit demonstrates high consistency with the marketed imported kit for in vitro detection of MTB-specific T-cell immune responses in fresh peripheral venous anticoagulated blood from suspected tuberculosis patients. It can be considered a viable alternative diagnostic tool for suspected tuberculosis patients.

Key words: Tuberculosis, Enzyme-linked immunosorbent assay, Reagent kits, diagnostic, Sensitivity and specificity

中图分类号: